Background: The aim of this study was to examine the influence of ezetimibe in addition to atorvastatin on plaque composition in patients with first-time ST-segment Elevation Myocardial Infarction treated with primary percutaneous intervention.
Methods: Eighty-seven patients were randomized (1:1) to ezetimibe 10mg or placebo in addition to Atorvastatin 80mg. Intravascular ultrasound with iMap was performed at baseline and after 12months in a non-infarct-related artery. Primary endpoint was change in necrotic core (NC). Secondary endpoints were total atheroma volume (TAV) and percentage atheroma volume (PAV).
Results: NC did not change significantly: ezetimibe group 24.9 (11.9, 51.3) mm to 24.9 (15.3, 54.5) mm, p=0.76, placebo group 29.4 (16.3, 78.5) mm to 32.0 (16.0, 88.7) mm, p=0.30, (p=0.35 between groups). TAV was reduced in the ezetimibe group only: ezetimibe (200.0 (135.6, 311.9) mm to 189.3 (126.4, 269.1) mm, p<0.001) compared to placebo group (218.4 (163.5, 307.9) mm to 212.2 (149.9, 394.8) mm, p=0.07) (p=0.56 between groups). PAV was reduced in the ezetimibe group only (40.1±8.6% to 39.2±9.0%, p=0.036) compared to placebo group (43.3±9.4% to 42.2±10.7%, p=0.07), p=0.91 between groups.
Conclusions: Ezetimibe in addition to atorvastatin therapy did not influence NC content, but was associated with regression of coronary atherosclerosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.carrev.2016.11.010 | DOI Listing |
Arch Cardiovasc Dis
December 2024
Department of Cardiology, CHU Montpellier, 34295 Montpellier, France.
Background: Recommended treatment after acute coronary syndrome (ACS) involves high-intensity statin therapy to achieve the low-density lipoprotein (LDL-C) target of<1.4mmol/L (European guidelines), but many patients discontinue statins because of real or perceived side-effects. Whether body mass index (BMI) influences statin intolerance remains unclear.
View Article and Find Full Text PDFCurr Atheroscler Rep
November 2024
Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences (DiSFeB), University of Milan, Milan, Italy.
Purpose Of Review: To consolidate key information on the efficacy and safety of ezetimibe, with a focus on the latest evidence.
Recent Findings: While ezetimibe has long been used alongside statins to help achieve lipid goals when statins are insufficient or in statin-intolerant patients, recent studies confirm and extend its benefits. Ezetimibe, when added to statins, is now recognized as an effective option for high-risk cardiovascular patients.
Virus Res
December 2024
Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241, PR China; Jiangsu Co-Innovation Center for the Prevention and Control of Important Animal Infectious Disease and Zoonosis, Yangzhou University, Yangzhou 225009, PR China. Electronic address:
Porcine epidemic diarrhea virus (PEDV) is a highly contagious virus that poses a serious threat to the global pig industry. Despite extensive efforts, the mechanism underlying virus entry for PEDV remains elusive. In this study, we first identified PEDV-susceptible and non-susceptible cell lines by using PEDV spike pseudotyped vesicular stomatitis virus.
View Article and Find Full Text PDFIndian Heart J
December 2024
Cardiothoracic Surgery, Medanta- The Medicity, Gurgaon, India. Electronic address:
This study aimed to assess the effectiveness of current lipid-lowering therapy in achieving low-density lipoprotein cholesterol (LDL-C) goals in Indian patients undergoing coronary revascularization. Consecutive subjects (n = 1275, mean age 60.0 ± 9.
View Article and Find Full Text PDFRedox Biol
December 2024
Cardiovascular Center, Department of Internal Medicine, and Department of Medical Research, MacKay Memorial Hospital, Taipei, 10449, Taiwan. Electronic address:
Atherosclerosis caused major morbidity and mortality worldwide. Molecules possessing lipid-lowering and/or anti-inflammatory properties are potential druggable targets against atherosclerosis. We examined the anti-atherosclerotic effects of fluorescent gold nanoclusters (FANC), which were dihydrolipoic acid (DHLA)-capped 2-nm gold nanoparticles.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!